Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
31.70
+0.80 (2.59%)
May 29, 2025, 4:00 PM - Market closed
Avidity Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Cash & Equivalents | 254.2 | 219.87 | 185.08 | 340.4 | 320.45 | 321.46 | Upgrade
|
| Short-Term Investments | 1,126 | 1,282 | 410.27 | 270.33 | 85.1 | 6.68 | Upgrade
|
| Cash & Short-Term Investments | 1,380 | 1,501 | 595.35 | 610.73 | 405.54 | 328.14 | Upgrade
|
| Cash Growth | 50.66% | 152.20% | -2.52% | 50.59% | 23.59% | 246.95% | Upgrade
|
| Accounts Receivable | - | - | 1.11 | 2.36 | 0.9 | 1.2 | Upgrade
|
| Other Receivables | 36.58 | 28.22 | 7.52 | 1.51 | - | - | Upgrade
|
| Receivables | 36.58 | 28.22 | 8.62 | 3.88 | 0.9 | 1.2 | Upgrade
|
| Prepaid Expenses | 18.52 | 12.57 | 7.33 | 8.34 | 4.7 | 2.34 | Upgrade
|
| Total Current Assets | 1,435 | 1,542 | 611.31 | 622.94 | 411.14 | 331.68 | Upgrade
|
| Property, Plant & Equipment | 20.57 | 18.29 | 16.65 | 15.01 | 15.59 | 1.92 | Upgrade
|
| Other Long-Term Assets | 3.53 | 3.32 | 0.6 | 0.85 | 0.85 | 0.3 | Upgrade
|
| Total Assets | 1,459 | 1,564 | 628.56 | 638.8 | 427.58 | 333.9 | Upgrade
|
| Accounts Payable | 6.63 | 8.46 | 8.81 | 4.64 | 2.81 | 7.75 | Upgrade
|
| Accrued Expenses | 60.37 | 64.73 | 39.87 | 39.13 | 20.22 | 3.15 | Upgrade
|
| Current Portion of Leases | 3.88 | 3.84 | 3.64 | 3.11 | 1.77 | - | Upgrade
|
| Current Unearned Revenue | 13.98 | 20.99 | 28.37 | 5.04 | 4.86 | 3.69 | Upgrade
|
| Total Current Liabilities | 84.87 | 98.02 | 80.68 | 51.91 | 29.66 | 14.59 | Upgrade
|
| Long-Term Leases | 2.09 | 2.96 | 6.21 | 7.58 | 9.96 | 0.94 | Upgrade
|
| Long-Term Unearned Revenue | 43.4 | 37.96 | 40.9 | 1.24 | 6.53 | 12.15 | Upgrade
|
| Total Liabilities | 130.35 | 138.94 | 127.79 | 60.73 | 46.15 | 27.68 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| Additional Paid-In Capital | 2,335 | 2,315 | 1,071 | 939.31 | 566.16 | 372.76 | Upgrade
|
| Retained Earnings | -1,009 | -893.07 | -570.76 | -358.54 | -184.55 | -66.54 | Upgrade
|
| Comprehensive Income & Other | 2.77 | 2.9 | 0.13 | -2.7 | -0.19 | -0.01 | Upgrade
|
| Total Common Equity | 1,329 | 1,425 | 500.76 | 578.08 | 381.43 | 306.22 | Upgrade
|
| Shareholders' Equity | 1,329 | 1,425 | 500.76 | 578.08 | 381.43 | 306.22 | Upgrade
|
| Total Liabilities & Equity | 1,459 | 1,564 | 628.56 | 638.8 | 427.58 | 333.9 | Upgrade
|
| Total Debt | 5.97 | 6.8 | 9.85 | 10.69 | 11.73 | 0.94 | Upgrade
|
| Net Cash (Debt) | 1,374 | 1,495 | 585.5 | 600.04 | 393.81 | 327.2 | Upgrade
|
| Net Cash Growth | 51.52% | 155.29% | -2.42% | 52.37% | 20.36% | 265.01% | Upgrade
|
| Net Cash Per Share | 11.25 | 13.40 | 8.02 | 11.50 | 9.51 | 15.10 | Upgrade
|
| Filing Date Shares Outstanding | 120.54 | 120.21 | 79.72 | 70.81 | 47.75 | 37.58 | Upgrade
|
| Total Common Shares Outstanding | 120.51 | 119.89 | 79.28 | 69.77 | 47.75 | 37.57 | Upgrade
|
| Working Capital | 1,350 | 1,444 | 530.63 | 571.03 | 381.48 | 317.09 | Upgrade
|
| Book Value Per Share | 11.03 | 11.89 | 6.32 | 8.29 | 7.99 | 8.15 | Upgrade
|
| Tangible Book Value | 1,329 | 1,425 | 500.76 | 578.08 | 381.43 | 306.22 | Upgrade
|
| Tangible Book Value Per Share | 11.03 | 11.89 | 6.32 | 8.29 | 7.99 | 8.15 | Upgrade
|
| Machinery | 16.94 | 16.42 | 13.31 | 9.13 | 6.29 | 3.03 | Upgrade
|
| Construction In Progress | 7.19 | 3.96 | - | - | - | - | Upgrade
|
| Leasehold Improvements | 0.29 | 0.29 | 0.29 | 0.25 | 0.25 | 0.42 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.